Literature DB >> 22330613

Pharmacotherapy: Statins and new-onset diabetes--the important questions.

David Preiss, Naveed Sattar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22330613     DOI： 10.1038/nrcardio.2012.15

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  7 in total

1.  Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.

Authors:  David D Waters; Jennifer E Ho; David A DeMicco; Andrei Breazna; Benoit J Arsenault; Chuan-Chuan Wun; John J Kastelein; Helen Colhoun; Philip Barter
Journal:  J Am Coll Cardiol       Date:  2011-04-05       Impact factor: 24.094

2.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

Authors:  Annie L Culver; Ira S Ockene; Raji Balasubramanian; Barbara C Olendzki; Deidre M Sepavich; Jean Wactawski-Wende; Joann E Manson; Yongxia Qiao; Simin Liu; Philip A Merriam; Catherine Rahilly-Tierny; Fridtjof Thomas; Jeffrey S Berger; Judith K Ockene; J David Curb; Yunsheng Ma
Journal:  Arch Intern Med       Date:  2012-01-09

3.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

4.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Authors:  Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford
Journal:  Lancet       Date:  2010-02-16       Impact factor: 79.321

5.  Rosuvastatin in older patients with systolic heart failure.

Authors:  John Kjekshus; Eduard Apetrei; Vivencio Barrios; Michael Böhm; John G F Cleland; Jan H Cornel; Peter Dunselman; Cândida Fonseca; Assen Goudev; Peer Grande; Lars Gullestad; Ake Hjalmarson; Jaromir Hradec; András Jánosi; Gabriel Kamenský; Michel Komajda; Jerzy Korewicki; Timo Kuusi; François Mach; Vyacheslav Mareev; John J V McMurray; Naresh Ranjith; Maria Schaufelberger; Johan Vanhaecke; Dirk J van Veldhuisen; Finn Waagstein; Hans Wedel; John Wikstrand
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

6.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Authors:  Luigi Tavazzi; Aldo P Maggioni; Roberto Marchioli; Simona Barlera; Maria Grazia Franzosi; Roberto Latini; Donata Lucci; Gian Luigi Nicolosi; Maurizio Porcu; Gianni Tognoni
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

7.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321
  7 in total
  7 in total

1.  Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter].

Authors:  Henna Cederberg; Markku Laakso
Journal:  Diabetologia       Date:  2015-06-25       Impact factor: 10.122

Review 2.  Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?

Authors:  Ines Krass; Adrian T Walker; Gerald F Watts
Journal:  Int J Clin Pharm       Date:  2012-05-24

3.  Diabetogenic effect of statins: a double-edged sword?

Authors:  Ji Sung Yoon; Hyoung Woo Lee
Journal:  Diabetes Metab J       Date:  2013-12       Impact factor: 5.376

4.  Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects.

Authors:  Lidia Glodzik; Henry Rusinek; Angela Kamer; Elizabeth Pirraglia; Wai Tsui; Lisa Mosconi; Yi Li; Pauline McHugh; John Murray; Schantel Williams; Ricardo S Osorio; Catherine Randall; Tracy Butler; Anup Deshpande; Shankar Vallabhajolusa; Mony de Leon
Journal:  Alzheimers Dement (Amst)       Date:  2016-04-19

5.  Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells.

Authors:  Junlan Zhou; Min Cheng; Yu-Hua Liao; Yu Hu; Min Wu; Qing Wang; Bo Qin; Hong Wang; Yan Zhu; Xiu-Mei Gao; David Goukassian; Ting C Zhao; Yao-Liang Tang; Raj Kishore; Gangjian Qin
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

Review 6.  Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes: A Meta-Analysis.

Authors:  Na Fang; Wei Han; Dandan Gong; Yu Fan
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

7.  Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion.

Authors:  Vishal A Salunkhe; Inês G Mollet; Jones K Ofori; Helena A Malm; Jonathan L S Esguerra; Thomas M Reinbothe; Karin G Stenkula; Anna Wendt; Lena Eliasson; Jenny Vikman
Journal:  EBioMedicine       Date:  2016-07-09       Impact factor: 8.143
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.